皮肤恶性黑色素瘤肝转移患者行肝动脉化疗栓塞治疗后的反应、生存及预后因素。

Response, survival, and prognostic factors after hepatic arterial chemoembolization in patients with liver metastases from cutaneous melanoma.

机构信息

Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

出版信息

Cancer Invest. 2011 Jan;29(1):49-55. doi: 10.3109/07357907.2010.535052.

DOI:10.3109/07357907.2010.535052

Abstract

We reviewed the medical records of 42 patients with cutaneous melanoma metastatic to the liver who underwent hepatic artery chemoembolization (HACE) at our institution. HACE resulted in radiologic response (38.9%) or disease stabilization (47.2%) in most patients. The median overall survival (OS) and time to progression (TTP) of liver disease were 7.7 and 6 months, respectively. Patient's age, lactate dehydrogenase (LDH) levels, type of treatment, number of extrahepatic metastatic sites, and response to therapy were found to be significant predictors of OS after HACE. Prolonged survival was seen in patients who responded to HACE (p = .034).

摘要

我们回顾了在我院接受肝动脉化疗栓塞术（HACE）治疗的 42 例肝转移皮肤恶性黑色素瘤患者的病历。大多数患者的 HACE 治疗结果为影像学缓解（38.9%）或疾病稳定（47.2%）。中位总生存期（OS）和肝病进展时间（TTP）分别为 7.7 个月和 6 个月。患者年龄、乳酸脱氢酶（LDH）水平、治疗类型、肝外转移部位数量以及对治疗的反应被发现是 HACE 后 OS 的显著预测因素。对 HACE 有反应的患者的生存时间延长（p =.034）。